PURA - Puration Extraction Brand Goes Global With Foreign Hemp Growers Looking To Puration For CBD Extraction
May 31 2017 - 10:02AM
InvestorsHub NewsWire
Dallas, TX -- May 31, 2017
-- InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced the Company has engaged in negotiations
to partner with a large commercial foreign hemp grower toward an
agreement where PURA would execute all extraction operations for
the grower. Management indicates the Company has been
approached by multiple foreign growers about PURA’s U.S. Patented
extraction process licensed from NCM Biotech.
“I believe the word is getting out from the ongoing research
underway at reputable institutions that the efficacy potential of
the NCM Biotech extractions maybe greater than that of GW
Pharmaceutical’s [NASDAQ: GWPH] products and candidate
products,” said Brian Shibley, CEO of Puration.
NCM Biotech exclusively owns U.S. Patent No. 9,199,960 entitled
“METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS
INCLUDING THE CANNABIS PLANT.” The license of the
process to PURA is the first and only license NCM Biotech has
executed.
NCM Biotech’s
medical advisory team includes John N. Gaitanis,
MD., Director of Child Neurology at Tufts Medical Center/Floating
Hospital for Children; Lloyd R. Saberski, M.D., Associate
Professor of Anesthesiology and Chronic Pain Management, Yale
University, and John McMichael, Ph.D., President & CEO Beech
Tree Labs. Research and development with NCM Biotech’s
patented process has demonstrated a high potential for bringing FDA
approved pharmaceutical products to market for the treatment of
multiple neurological disorders and cancer.
PURA is dedicated to producing the best cannabinoid extractions
available on the market. The Company is becoming more widely
recognized for its cannabinoid extractions with the expansion the
EVERx CBD Infused Performance Sports Products using PURA extracts
in addition to the growing market awareness of NCM Biotech’s
research.
To learn more about Puration,
visit:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024